Standard-versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization

Azzurra Romeo, Anna Chierichini, Alessandra Spagnoli, Mariangela Vittori, Michele Vacca, Maria Gozzer, Antonio Spadea, Barbara Anaclerico, Maria Laura Dessanti, Mariella D'Andrea, Giuseppe Toglia, Luciana Annino, Maria Concetta Petti, Andrea Mengarelli, William Arcese

Research output: Contribution to journalArticlepeer-review


Background: The aim of this retrospective, multicenter study was to compare high-versus standard-dose lenograstim after chemotherapy in collecting target dose of CD34+ peripheral blood progenitor cells (PBPCs) in adult candidates for autologous transplant. STUDY DESIGN AND METHODS: A total of 166 consecutive patients (28 acute leukemias [ALs], 77 lymphomas, 61 multiple myeloma [MM]) underwent 182 mobilization procedures. Only the first were analyzed. The CD34+ cell target was at least 2 × 106, 4 × 106, and 8 × 106/kg and lenograstim started on days +19, +1, and +5 from the end of chemotherapy for AL, lymphomas, and MM, respectively. Eighty-seven and 79 patients, respectively, received 5 and 10 μg/kg/day lenograstim subcutaneously (sc). An analysis to evaluate factors predicting satisfactory procedures and outcome of transplants performed with first-mobilization-procedure PBPCs was conducted. Most patients received 6 mg of pegfilgrastim or 5 μg/kg/day lenograstim sc after transplant. RESULTS: In multivariate analysis, high-dose lenograstim (p = 0.053) in MM and male sex (p = 0.028) were positive predictive factors for reaching cell target. Fludarabine negatively influenced stimulation length (p = 0.002). Apheresis, CD34+ cells mobilized and collected, blood volume processed, side effects, transplants performed, and engraftment time were similar between lenograstim cohorts. Pegfilgrastim versus lenograstim delayed platelet (PLT) recovery times (13 days vs. 11 days, p = 0.036). CONCLUSIONS: High-dose lenograstim more efficiently mobilized MM patients requiring the highest PBPC target but did not influence transplants performed and engraftment time. Male patients mobilized more efficiently. Fludarabine negatively influenced stimulation length. Finally, pegfilgrastim seems to delay PLT recovery.

Original languageEnglish
Pages (from-to)2432-2446
Number of pages15
Issue number11
Publication statusPublished - Nov 2010

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Standard-versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization'. Together they form a unique fingerprint.

Cite this